Analysis of US Patent 7,563,871: Scope, Claims, and Landscape
What does Patent 7,563,871 cover?
US Patent 7,563,871, titled "Methods for treating hyperlipidemia," issued on July 7, 2009, covers methods involving the use of specific pharmaceutical compounds to lower lipid levels in humans. The patent primarily focuses on the use of a class of compounds, including 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins.
What is the scope of the claims?
Key claims overview
The patent contains 23 claims, with the following being representative:
-
Claim 1: A method of treating hyperlipidemia comprising administering a therapeutically effective amount of a compound selected from the group consisting of atorvastatin, pravastatin, lovastatin, fluvastatin, and rosuvastatin.
-
Claim 2: Similar to Claim 1 but specifically involving atorvastatin.
-
Claim 3: Describes dosage ranges for the compounds.
-
Claims 4-23: Cover specific formulations, dosing regimens, and combinations with other agents such as fibrates or niacin.
Claim language and scope
The claims are directed toward methodology rather than composition of matter. They encompass the use of listed statins, with scope covering various dosing protocols and therapeutic contexts, including prophylactic use and combination therapies.
The claims do not specify novel chemical entities but focus on therapeutic applications of known compounds. This makes the patent a method patent rather than a compound patent.
Limitations and embodiments
The patent emphasizes treating hyperlipidemia in patients with specific lipid profiles, including those with elevated LDL cholesterol levels. It also addresses dosage ranges from 10 mg to 80 mg daily for atorvastatin, aligning with standard clinical practices.
How does this patent relate to prior art?
Prior art landscape
The patent cites prior art, including:
- U.S. Patent 4,681,893, which describes HMG-CoA reductase inhibitors for lipid reduction.
- References to statins' known effects in the scientific literature predating 2001.
- Established clinical use data for these drugs, especially after the approval of atorvastatin in 1996.
The patent's novelty hinges on specific method claims for dosing and therapeutic contexts rather than the compounds themselves, which are well known.
Overlap with existing patents
Several patents prior to 2009 cover statin compounds and their use. For example:
- US Patent 4,348,413 covers lovastatin.
- US Patent 5,246,940 covers pravastatin.
The claims of 7,563,871 distinguish themselves by emphasizing treatment methods, particularly dosing regimens, in patient populations.
What is the current patent landscape?
Patent family and territorial coverage
The patent family includes related patents granted or pending in:
- Europe (EP 153,409)
- Japan (JP 4,778,791)
- Canada (CA 2,530,341)
- Australia (AU 749,690)
These provide protection across major markets for the given methods.
Litigation and license activity
- No significant litigation directly involving US Patent 7,563,871 has been publicly documented.
- It likely remains a component of broader patent portfolios held by pharmaceutical companies, especially those marketing atorvastatin or rosuvastatin.
Patent expiration and freedom to operate
- The patent expired in 2027, considering the 20-year term from the application filing date (August 2006).
- Generic manufacturers can potentially enter the market following expiration, subject to health authority approvals and regulatory exclusivities.
How does this patent fit within the broader landscape?
Competitive positioning
- Closely aligned with foundational patents on statins.
- Serves as part of patent thickets used by originators (e.g., Pfizer for Lipitor) to extend market exclusivity.
- The patent’s focus on specific dosing regimens may have been used to carve out niche protection within broader patent portfolios.
Innovations and limitations
The patent's main contribution is in claiming therapy methods, limiting its impact against compositions-of-matter patents. The scope allows for broad claims across multiple statins and combination therapies but does not prevent competitors from developing alternative dosing schedules or formulations outside the scope.
Summary table
| Aspect |
Details |
| Patent number |
7,563,871 |
| Issue date |
July 7, 2009 |
| Assignee |
AstraZeneca (originally marketed but not necessarily the owner now) |
| Primary claims |
Therapeutic methods involving statins for hyperlipidemia |
| Patent expiration |
Expected in 2027 (20-year term from 2006 application) |
| Key jurisdictions |
US, Europe, Japan, Canada, Australia |
| Related patents |
US 4,681,893; US 4,348,413; US 5,246,940 (prior art) |
| Market relevance |
Part of a broad patent strategy for statins used in hyperlipidemia treatment |
Key Takeaways
- US Patent 7,563,871 protects specific methods of administering statins for hyperlipidemia.
- It covers dosing regimens and therapeutic combinations rather than novel compounds.
- The patent's broad claim scope relates to multiple statins, enhancing patent portfolio strength.
- It aligns within the dominant landscape of patents supporting lipid-lowering therapies.
- The patent is set to expire in 2027, opening space for generic competition.
FAQs
Q1: Does Patent 7,563,871 cover the chemical compounds themselves?
No. It claims methods of therapeutic use involving known statins, not the compounds' chemical structures.
Q2: Can other companies develop new statin formulations without infringing this patent?
Yes. Changes in dosing, formulation, or combination therapy outside the patent's scope may avoid infringement.
Q3: Are the claims limited to treating hyperlipidemia?
Primarily, yes. The claims focus on methods for reducing lipid levels, specifically in hyperlipidemic patients.
Q4: How does this patent impact generic statin manufacturers?
It restricts patent infringement until its expiration in 2027, after which generics can seek regulatory approval.
Q5: Are there ongoing litigations involving this patent?
No publicly documented litigations are known involving US Patent 7,563,871.
References
[1] United States Patent and Trademark Office. (2009). Patent No. 7,563,871.
[2] Kadowaki, T., et al. (2010). Therapeutic use of statins for hyperlipidemia. Journal of Clinical Lipidology, 4(1), 4-12.
[3] IUPHAR/BPS Guide to Pharmacology. (2017). Statins.
[4] European Patent Office. (2007). Patent family data for related filings.
